Denver, May 20, 2025 (Business Wire) * DaVita Inc. (NYSE: DVA) has announced the upsize and pricing of its private offering of 6.750% senior notes due 2033. The aggregate principal amount of the 2033 notes offered in the offering was increased from $750 million to $1 billion, and the 2033 notes were priced at 100.000% of their face amount to yield a 6.750% coupon. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closing conditions.
DaVita intends to use the net proceeds from the offering to repay outstanding revolving credit facility borrowings, together with related accrued and unpaid interest thereon, to pay any costs, fees, and expenses in connection with the foregoing, and if any proceeds remain, for general corporate purposes, including, without limitation, for repurchases of capital stock, working capital, and capital expenditures.
The 2033 notes were offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and to certain non-U.S. persons in transactions outside the United States in compliance with Regulation S under the Securities Act.
DaVita (NYSE: DVA) is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. As a comprehensive kidney care provider, Davita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As a result of these announcements, the company's shares have moved 0.56% on the market, and are now trading at a price of $145.77. For the full picture, make sure to review DAVITA INC.'s 8-K report.
